TriSalus Life Sciences, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported sales was USD 5.72 million compared to USD 3.23 million a year ago. Net loss was USD 35.51 million compared to USD 22.54 million a year ago. Basic loss per share from continuing operations was USD 1.56 compared to USD 75.01 a year ago.

For the full year, the company reported sales was USD 18.51 million compared to USD 12.4 million a year ago. Net loss was USD 59.04 million compared to USD 47.19 million a year ago. Basic loss per share from continuing operations was USD 6.73 compared to USD 161.55 a year ago.